Does Rhofade reduce persistent redness?

How does Rhofade work?

Rhofade (oxymetazoline hydrochloride cream) is a topical ophthalmic vasoconstrictor used to treat persistent facial erythema (redness) associated with rosacea in adults. [1] The active ingredient, oxymetazoline, belongs to a class of medications known as alpha-adrenergic agonists, which constrict blood vessels to reduce facial redness.

Efficacy of Rhofade in reducing persistent redness

Studies have shown that Rhofade is effective in reducing persistent redness associated with rosacea. In a multicenter, randomized, double-blind, placebo-controlled trial, participants applied a 1% oxymetazoline cream (Rhofade) twice daily for 30 days. Compared to the placebo group, the Rhofade group showed a significant reduction in facial erythema, as measured by a clinician's assessment and by facial erythema photographic images. [2]

Clinical significance of Rhofade efficacy

The reduction in facial erythema associated with Rhofade is clinically significant, particularly for individuals with rosacea who experience persistent redness, which can impact their daily lives and overall quality of life. [3]

Comparison to other treatments

Rhofade is a topical cream, which offers a convenient and localized treatment option for patients with persistent redness associated with rosacea. In comparison, oral antibiotics and retinoids are often used to treat rosacea but may have systemic side effects and require longer treatment durations. [4]

Patent information

Rhofade was first approved in 2019, and the U.S. patent for oxymetazoline hydrochloride cream expired in 2026. [5]

In conclusion, Rhofade is effective in reducing persistent redness associated with rosacea, offering a convenient and localized treatment option for individuals who experience this symptoms.

Sources:

[1] Rhofade prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209142s001lbl.pdf
[2] J Drugs Dermatol. 2019;18(3):247-255.
[3] J Am Acad Dermatol. 2019;80(3):654-662.
[4] Int J Dermatol. 2018;57(5):535-546.
[5] DrugPatentWatch.com. U.S. patent expiration dates. https://drugpatentwatch.com/expires/oxymetazoline-hydrochloride